SK15642000A3 - SPâSOB KONVERZIE PEPTIDOV TRIEDY ECHINOKANDÖNOV NA ICH C4-HOMOTYROZÖNMONODEOXYANALŕGY - Google Patents

SPâSOB KONVERZIE PEPTIDOV TRIEDY ECHINOKANDÖNOV NA ICH C4-HOMOTYROZÖNMONODEOXYANALŕGY Download PDF

Info

Publication number: SK15642000A3
Authority: SK; Slovakia
Prior art keywords: con; deoxypneumocandin; pneumocandin; mulundocandin; homotyrosine
Prior art date: 1998-04-23

Application number

SK1564-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Triptikumar Mukhopadhyay

Kenia Jayvanti

Erra Koteswara Satya Vijava Kumar

Original Assignee

Aventis Pharma Deutschland Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-23

Filing date

1999-04-22

Publication date

2001-09-11

1999-04-22 Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh

2001-09-11 Publication of SK15642000A3 publication Critical patent/SK15642000A3/sk

Links

108010049047 Echinocandins Proteins 0.000 title claims abstract description 24
238000000034 method Methods 0.000 title claims abstract description 17
108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 9
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 9
238000006243 chemical reaction Methods 0.000 title abstract description 5
GWBOEEVOSDBARW-SPXLVGSKSA-N C([C@@H](O)[C@H]1C(=O)N[C@@H](CO)C(=O)N2C[C@H](C)[C@H](O)[C@H]2C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N1)[C@@H](C)O)=O)NC(=O)CCCCCCCCCCC(C)CC)C1=CC=C(O)C=C1 Chemical compound C([C@@H](O)[C@H]1C(=O)N[C@@H](CO)C(=O)N2C[C@H](C)[C@H](O)[C@H]2C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N1)[C@@H](C)O)=O)NC(=O)CCCCCCCCCCC(C)CC)C1=CC=C(O)C=C1 GWBOEEVOSDBARW-SPXLVGSKSA-N 0.000 claims abstract description 13
WUPSJTQKGFMDON-UHFFFAOYSA-N Mulundocandin Natural products N1C(=O)C2CC(O)CN2C(=O)C(C(C)O)NC(=O)C(NC(=O)CCCCCCCCCCC(C)CC)CC(O)C(O)NC(=O)C2C(O)C(C)CN2C(=O)C(CO)NC(=O)C1C(O)C(O)C1=CC=C(O)C=C1 WUPSJTQKGFMDON-UHFFFAOYSA-N 0.000 claims abstract description 13
WUPSJTQKGFMDON-FUMJLYDLSA-N N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-3-(hydroxymethyl)-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-12-methyltetradecanamide Chemical compound CCC(C)CCCCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)C(O)c1ccc(O)cc1 WUPSJTQKGFMDON-FUMJLYDLSA-N 0.000 claims abstract description 13
108010063315 deoxymulundocandin Proteins 0.000 claims abstract description 13
108010084578 mulundocandin Proteins 0.000 claims abstract description 13
150000001875 compounds Chemical class 0.000 claims abstract description 9
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 8
LOOZZTFGSTZNRX-VIFPVBQESA-N L-Homotyrosine Chemical compound OC(=O)[C@@H](N)CCC1=CC=C(O)C=C1 LOOZZTFGSTZNRX-VIFPVBQESA-N 0.000 claims abstract description 4
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims abstract description 4
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims abstract description 4
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims abstract description 4
238000010511 deprotection reaction Methods 0.000 claims abstract description 4
230000007935 neutral effect Effects 0.000 claims abstract description 4
229960003104 ornithine Drugs 0.000 claims abstract description 4
239000011541 reaction mixture Substances 0.000 claims abstract description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
239000007868 Raney catalyst Substances 0.000 claims description 6
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims description 6
229910000564 Raney nickel Inorganic materials 0.000 claims description 6
125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
-1 10,12-dimethyl myristoyl Chemical group 0.000 claims description 5
108010062092 echinocandin B Proteins 0.000 claims description 3
FAUOJMHVEYMQQG-HVYQDZECSA-N echinocandin B Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@@H](C)O)=CC=C(O)C=C1 FAUOJMHVEYMQQG-HVYQDZECSA-N 0.000 claims description 3
108010062096 echinocandin C Proteins 0.000 claims description 3
NZZDHXBKVFENNY-YBPCKFEPSA-N echinocandin c Chemical compound C([C@@H](O)[C@H]1C(=O)N[C@H](C(=O)N2C[C@H](C)[C@H](O)[C@H]2C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N1)[C@@H](C)O)=O)NC(=O)CCCCCCC\C=C/C\C=C/CCCCC)[C@@H](C)O)C1=CC=C(O)C=C1 NZZDHXBKVFENNY-YBPCKFEPSA-N 0.000 claims description 3
238000007327 hydrogenolysis reaction Methods 0.000 claims description 3
RTMQLLLPNLXDSP-LORNMRFGSA-N pneumocandin a2 Chemical compound C1([C@@H](O)C(O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)NCCCC(C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCC(C)CC(C)CC)[C@H](O)CC(N)=O)=CC=C(O)C=C1 RTMQLLLPNLXDSP-LORNMRFGSA-N 0.000 claims description 3
CAUDURDUCQQHDE-UVQGGVJESA-N pneumocandin b2 Chemical compound C1([C@@H](O)C(O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)NCCCC(C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCC(C)CC(C)CC)[C@H](O)CC(N)=O)=CC=C(O)C=C1 CAUDURDUCQQHDE-UVQGGVJESA-N 0.000 claims description 3
125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims description 2
IPMHTGKXJQHTQV-YWVCOZMLSA-N 6-(trans-4-hydroxy-l-proline)-pneumocandin bo Chemical compound C1([C@@H](O)C(O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](O)[C@@H](O)CC(C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCC(C)CC(C)CC)[C@H](O)CC(N)=O)=CC=C(O)C=C1 IPMHTGKXJQHTQV-YWVCOZMLSA-N 0.000 claims 1
DFQUSLQYURJBIT-MFKXNLKNSA-N C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCC(C)CC(C)CC)[C@H](O)CC(N)=O)=CC=C(O)C=C1 Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCC(C)CC(C)CC)[C@H](O)CC(N)=O)=CC=C(O)C=C1 DFQUSLQYURJBIT-MFKXNLKNSA-N 0.000 claims 1
125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
DQXPFAADCTZLNL-FXDJFZINSA-N pneumocandin B0 Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CC(N)=O)=CC=C(O)C=C1 DQXPFAADCTZLNL-FXDJFZINSA-N 0.000 claims 1
238000006722 reduction reaction Methods 0.000 claims 1
238000000746 purification Methods 0.000 abstract description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
230000005526 G1 to G0 transition Effects 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
239000002904 solvent Substances 0.000 description 3
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
229920002498 Beta-glucan Polymers 0.000 description 2
241000222122 Candida albicans Species 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000843 anti-fungal effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229940095731 candida albicans Drugs 0.000 description 2
238000004185 countercurrent chromatography Methods 0.000 description 2
238000004821 distillation Methods 0.000 description 2
239000003480 eluent Substances 0.000 description 2
238000010265 fast atom bombardment Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000004460 liquid liquid chromatography Methods 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
238000004366 reverse phase liquid chromatography Methods 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000228245 Aspergillus niger Species 0.000 description 1
241001277988 Aspergillus sydowii Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000233870 Pneumocystis Species 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
206010035742 Pneumonitis Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
201000000317 pneumocystosis Diseases 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000010414 supernatant solution Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/19—Antibiotic
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/27—Cyclic peptide or cyclic protein

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SK1564-2000A 1998-04-23 1999-04-22 SPâSOB KONVERZIE PEPTIDOV TRIEDY ECHINOKANDÖNOV NA ICH C4-HOMOTYROZÖNMONODEOXYANALŕGY SK15642000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP98107397		1998-04-23
PCT/EP1999/002715 WO1999055727A1 (en)	1998-04-23	1999-04-22	A process for the conversion of echinocandin class of peptides to their c4-homotyrosine monodeoxy analogues

Publications (1)

Publication Number	Publication Date
SK15642000A3 true SK15642000A3 (sk)	2001-09-11

Family

ID=8231807

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1564-2000A SK15642000A3 (sk)	1998-04-23	1999-04-22	SPâSOB KONVERZIE PEPTIDOV TRIEDY ECHINOKANDÖNOV NA ICH C4-HOMOTYROZÖNMONODEOXYANALŕGY

Country Status (34)

Country	Link
US (1)	US6809177B1 (de)
EP (1)	EP1073675B1 (de)
JP (1)	JP2002513033A (de)
KR (1)	KR20010042916A (de)
CN (1)	CN1298410A (de)
AP (1)	AP1111A (de)
AT (1)	ATE350392T1 (de)
AU (1)	AU758395B2 (de)
BG (1)	BG104772A (de)
BR (1)	BR9909853A (de)
CA (1)	CA2327474A1 (de)
CY (1)	CY1106456T1 (de)
CZ (1)	CZ293547B6 (de)
DE (1)	DE69934683T2 (de)
DK (1)	DK1073675T3 (de)
EA (1)	EA002909B1 (de)
EE (1)	EE200000611A (de)
ES (1)	ES2280119T3 (de)
GE (1)	GEP20032900B (de)
HR (1)	HRP20000719A2 (de)
HU (1)	HUP0102491A3 (de)
ID (1)	ID27026A (de)
IL (1)	IL138432A0 (de)
NO (1)	NO20005258L (de)
NZ (1)	NZ506667A (de)
PL (1)	PL343484A1 (de)
PT (1)	PT1073675E (de)
SI (1)	SI1073675T1 (de)
SK (1)	SK15642000A3 (de)
TR (1)	TR200003058T2 (de)
UA (1)	UA64787C2 (de)
WO (1)	WO1999055727A1 (de)
YU (1)	YU65000A (de)
ZA (1)	ZA200004600B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101993477B (zh) *	2009-08-18	2014-03-26	上海医药工业研究院	一种棘白菌素b的脱氧类似物的制备方法
CA2794688C (en) *	2010-03-29	2018-07-03	Biocon Limited	A process for purification of pneumocandin
CN102464704B (zh) *	2010-11-05	2013-12-11	上海医药工业研究院	一种化合物及其制备方法和用途
CN116925187A (zh)	2022-04-07	2023-10-24	浙江大学	棘白菌素类化合物及其制备方法和用途
KR102866737B1 (ko) *	2022-04-26	2025-10-01	전남대학교 산학협력단	타이로신 3-모노옥시제네이즈 유사 유전자가 도입된 지질 생산성이 향상된 미생물 및 이를 이용한 지질 생산 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5159059A (en) *	1990-05-29	1992-10-27	Merck & Co., Inc.	Process for reduction of certain cyclohexapeptide compounds
US5939384A (en)	1991-10-01	1999-08-17	Merck & Co., Inc.	Cyclohexapeptidyl propanolamine compounds
US5348940A (en)	1991-10-01	1994-09-20	Merck & Co., Inc.	Cyclohexapeptidyl hydroxypropionitrile compounds
AU681119B2 (en)	1993-05-17	1997-08-21	Fujisawa Pharmaceutical Co., Ltd.	New polypeptide compound and a process for preparation thereof
JP3118466B2 (ja) *	1994-08-23	2000-12-18	メルクエンドカンパニーインコーポレーテッド	シクロヘキサペプチジルリポペプチドの側鎖誘導体の改良製造方法
WO1996008266A1 (en)	1994-09-16	1996-03-21	Merck & Co., Inc.	Aza cyclohexapeptide compounds
JPH10508852A (ja) *	1994-11-15	1998-09-02	イーライ・リリー・アンド・カンパニー	レトロアルドール反応操作のための方法

1999
- 1999-04-22 ID IDW20002148A patent/ID27026A/id unknown
- 1999-04-22 JP JP2000545885A patent/JP2002513033A/ja active Pending
- 1999-04-22 SK SK1564-2000A patent/SK15642000A3/sk unknown
- 1999-04-22 BR BR9909853-9A patent/BR9909853A/pt not_active Application Discontinuation
- 1999-04-22 IL IL13843299A patent/IL138432A0/xx unknown
- 1999-04-22 NZ NZ506667A patent/NZ506667A/xx unknown
- 1999-04-22 CA CA002327474A patent/CA2327474A1/en not_active Abandoned
- 1999-04-22 US US09/673,836 patent/US6809177B1/en not_active Expired - Fee Related
- 1999-04-22 SI SI9930951T patent/SI1073675T1/sl unknown
- 1999-04-22 DE DE69934683T patent/DE69934683T2/de not_active Expired - Fee Related
- 1999-04-22 CZ CZ20003903A patent/CZ293547B6/cs not_active IP Right Cessation
- 1999-04-22 KR KR1020007011728A patent/KR20010042916A/ko not_active Ceased
- 1999-04-22 DK DK99919261T patent/DK1073675T3/da active
- 1999-04-22 AT AT99919261T patent/ATE350392T1/de not_active IP Right Cessation
- 1999-04-22 PL PL99343484A patent/PL343484A1/xx not_active IP Right Cessation
- 1999-04-22 UA UA2000116619A patent/UA64787C2/uk unknown
- 1999-04-22 ES ES99919261T patent/ES2280119T3/es not_active Expired - Lifetime
- 1999-04-22 CN CN99805330A patent/CN1298410A/zh active Pending
- 1999-04-22 AP APAP/P/2000/001894A patent/AP1111A/en active
- 1999-04-22 AU AU37096/99A patent/AU758395B2/en not_active Ceased
- 1999-04-22 TR TR2000/03058T patent/TR200003058T2/xx unknown
- 1999-04-22 GE GEAP19995615A patent/GEP20032900B/en unknown
- 1999-04-22 HU HU0102491A patent/HUP0102491A3/hu unknown
- 1999-04-22 EE EEP200000611A patent/EE200000611A/xx unknown
- 1999-04-22 YU YU65000A patent/YU65000A/sh unknown
- 1999-04-22 EA EA200001099A patent/EA002909B1/ru not_active IP Right Cessation
- 1999-04-22 HR HR20000719A patent/HRP20000719A2/hr not_active Application Discontinuation
- 1999-04-22 PT PT99919261T patent/PT1073675E/pt unknown
- 1999-04-22 WO PCT/EP1999/002715 patent/WO1999055727A1/en not_active Ceased
- 1999-04-22 EP EP99919261A patent/EP1073675B1/de not_active Expired - Lifetime
2000
- 2000-09-01 ZA ZA200004600A patent/ZA200004600B/en unknown
- 2000-09-18 BG BG104772A patent/BG104772A/xx unknown
- 2000-10-19 NO NO20005258A patent/NO20005258L/no not_active Application Discontinuation
2007
- 2007-03-22 CY CY20071100402T patent/CY1106456T1/el unknown

Also Published As

Publication number	Publication date
IL138432A0 (en)	2001-10-31
AP1111A (en)	2002-10-23
CN1298410A (zh)	2001-06-06
PL343484A1 (en)	2001-08-27
PT1073675E (pt)	2007-03-30
EA200001099A1 (ru)	2001-04-23
NZ506667A (en)	2003-02-28
EA002909B1 (ru)	2002-10-31
SI1073675T1 (sl)	2007-04-30
ES2280119T3 (es)	2007-09-01
CZ20003903A3 (en)	2001-05-16
ZA200004600B (en)	2002-01-30
CA2327474A1 (en)	1999-11-04
EP1073675B1 (de)	2007-01-03
JP2002513033A (ja)	2002-05-08
DK1073675T3 (da)	2007-05-07
DE69934683T2 (de)	2007-10-18
CZ293547B6 (cs)	2004-06-16
WO1999055727A1 (en)	1999-11-04
KR20010042916A (ko)	2001-05-25
NO20005258D0 (no)	2000-10-19
HRP20000719A2 (en)	2001-10-31
ID27026A (id)	2001-02-22
GEP20032900B (en)	2003-02-25
EE200000611A (et)	2002-04-15
ATE350392T1 (de)	2007-01-15
TR200003058T2 (tr)	2001-01-22
UA64787C2 (en)	2004-03-15
YU65000A (sh)	2003-10-31
CY1106456T1 (el)	2011-10-12
US6809177B1 (en)	2004-10-26
DE69934683D1 (de)	2007-02-15
EP1073675A1 (de)	2001-02-07
AU758395B2 (en)	2003-03-20
AP2000001894A0 (en)	2000-09-30
NO20005258L (no)	2000-10-19
BG104772A (en)	2001-04-30
HUP0102491A3 (en)	2001-12-28
HUP0102491A2 (hu)	2001-11-28
BR9909853A (pt)	2000-12-19
AU3709699A (en)	1999-11-16

Publication	Publication Date	Title
US6239104B1 (en)	2001-05-29	Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
Al-Obeidi et al.	1989	Potent and prolonged-acting cyclic lactam analogs of. alpha.-melanotropin: design based on molecular dynamics
Hossain et al.	1988	Crystal and molecular structure of didemnin B, an antiviral and cytotoxic depsipeptide.
SE461334B (sv)	1990-02-05	Cyklosporinderivat, foerfarande foer framstaellning daerav samt farmaceutisk komposition innehaallande naemnda derivat
CA2059380A1 (en)	1992-07-25	Endothelin receptor antagonists isolated from microbispora
CN1304309A (zh)	2001-07-18	半合成海鞘素
EP0459564A2 (de)	1991-12-04	Reduktionsverfahren für Echinocandin-ähnliche Zyklohexapeptidverbindungen
CN113651874A (zh)	2021-11-16	一种具有抑制念珠菌生长繁殖作用的订书肽及其制备方法和应用
SK15642000A3 (sk)	2001-09-11	SPâSOB KONVERZIE PEPTIDOV TRIEDY ECHINOKANDÖNOV NA ICH C4-HOMOTYROZÖNMONODEOXYANALŕGY
ANWER et al.	1990	Backbone modifications in cyclic pep tides Conformational analysis of a cyclic pseudopentapeptide containing a thiomethylene ether amide bond replacement
WO1994009033A1 (en)	1994-04-28	An improved process for cyclohexapeptidyl bisamine compounds
FUJITA et al.	1990	Studies on Analgesic Oligopeptides. VI.: Further Studies of Synthesis and Biological Properties of Tripeptide Alkylamides, Try-D-Arg-Phe-X
Lammek et al.	1998	Biologically active analogues of arginine vasopressin containing conformationally restricted dipeptide fragments
MXPA00010297A (en)	2002-05-09	A process for the conversion of echinocandin class of peptides to their c4-homotyrosine monodeoxy analogues
EP1204677B1 (de)	2008-12-03	Cyclohexapeptide, deren herstellung und verwendung in pharmazeutische zusammensetzungen
EP0894092B1 (de)	2002-04-03	Zyklisches heptapeptidderivat der kolonialen ascidians, lissoclinum sp
HK1037641A (en)	2002-02-15	A process for the conversion of echinocandin class of peptides to their c4-homotyrosine monodeoxy analogues
EP2352746A1 (de)	2011-08-10	Bioaktive verbindungen
US5854212A (en)	1998-12-29	Cyclohexapeptidyl bisamine compound, compositions containing said compound and methods of use
Kurome et al.	1993	Total Synthesis of Aureobasidin A, an Antifungal Cyclic Depsipeptide.
US20040033940A1 (en)	2004-02-19	Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP
CA2445216A1 (en)	2002-10-31	Process for producing glycopeptide antibiotic by cultivating streptomyces hygroscopicus strains
HU193039B (en)	1987-08-28	Process for preparing a-21978c cyclic n-substituted peptide derivatives